ADX vs. IBB, HTGC, DNP, PTY, USA, NUV, GSBD, TY, GAB, and RVT
Should you be buying Adams Diversified Equity Fund stock or one of its competitors? The main competitors of Adams Diversified Equity Fund include iShares Biotechnology ETF (IBB), Hercules Capital (HTGC), DNP Select Income Fund (DNP), PIMCO Corporate & Income Opportunity Fund (PTY), Liberty All-Star Equity Fund (USA), Nuveen Municipal Value Fund (NUV), Goldman Sachs BDC (GSBD), Tri-Continental (TY), The Gabelli Equity Trust (GAB), and Royce Value Trust (RVT). These companies are all part of the "investment offices, not elsewhere classified" industry.
Adams Diversified Equity Fund (NYSE:ADX) and iShares Biotechnology ETF (NASDAQ:IBB) are both mid-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends, profitability and community ranking.
Given iShares Biotechnology ETF's higher probable upside, analysts clearly believe iShares Biotechnology ETF is more favorable than Adams Diversified Equity Fund.
iShares Biotechnology ETF received 13 more outperform votes than Adams Diversified Equity Fund when rated by MarketBeat users. Likewise, 67.09% of users gave iShares Biotechnology ETF an outperform vote while only 53.09% of users gave Adams Diversified Equity Fund an outperform vote.
28.4% of Adams Diversified Equity Fund shares are held by institutional investors. Comparatively, 62.5% of iShares Biotechnology ETF shares are held by institutional investors. 0.1% of Adams Diversified Equity Fund shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Adams Diversified Equity Fund has a beta of 1, indicating that its stock price has a similar volatility profile to the S&P 500.Comparatively, iShares Biotechnology ETF has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.
In the previous week, Adams Diversified Equity Fund and Adams Diversified Equity Fund both had 3 articles in the media. iShares Biotechnology ETF's average media sentiment score of 0.47 beat Adams Diversified Equity Fund's score of 0.02 indicating that iShares Biotechnology ETF is being referred to more favorably in the news media.
Adams Diversified Equity Fund pays an annual dividend of $1.30 per share and has a dividend yield of 6.4%. iShares Biotechnology ETF pays an annual dividend of $0.41 per share and has a dividend yield of 0.3%.
Summary
iShares Biotechnology ETF beats Adams Diversified Equity Fund on 6 of the 9 factors compared between the two stocks.
Get Adams Diversified Equity Fund News Delivered to You Automatically
Sign up to receive the latest news and ratings for ADX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ADX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Adams Diversified Equity Fund Competitors List
Related Companies and Tools
